LRRK2 and essential thrombocythemia: Furthermore, our group previously demonstrated an association between the known PD risk variant LRRK2 R1628P with ET, where R1628P carriers had a two-fold risk of developing ET (OR = 2.20, 95% CI = 1.30–3.73, p = 0.0035)22.